Analysts fell to the sidelines weighing in on and Regeneron (REGN) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Regeneron (REGN)
In a report issued on October 30, Cory Kasimov from J.P. Morgan maintained a Hold rating on Regeneron. The company’s shares closed last Wednesday at $470.09.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 22.2% and a 56.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $681.73 average price target, implying a 42.9% upside from current levels. In a report issued on November 5, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN: